Key Drivers
- Improving liquidity
- Reduced opex burn
- Persistent net losses
AIAI Summary
Tilray's shift to a beverage‑first CPG and international medical/pharma distributor reframes the investment case away from a pure cannabis‑reform bet toward one that will live or die on rapid beverage integration, SKU rationalization, margin recovery, and timely execution of European/Australian distribution deals. The actionable takeaway: success in relistings, margin improvement and receivables collection could drive a re‑rating, but modest net cash (~$30M), large intangibles/inventory and permit/implementation risk make execution failures likely catalysts for impairments and downside.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Improving liquidity
- •Reduced opex burn
- •Persistent net losses
TLRY shows improving liquidity and margin trends—higher cash and current ratio plus sharply reduced opex/EBITDA losses—while still loss-making with large accumulated deficits and concentrated intangible/inventory risk.
Price Behavior
Key Price Behavior Insights:
- •Short-term decline
- •Fresh local low
- •Resistance cluster
Stock is in a clear short-term downtrend—about a 20% drop over the last month that made a fresh local low on 2026-03-20, leaving little nearby support but a resistance band near the high-$7s–$8.00 area and potential short-term oversold bounce.
~20% drop over the last month culminating in a new local low on 2026-03-20
Sentiment & News
Key News Insights:
- •Beverage pivot
- •Cross‑border expansion
- •Investor skepticism
Tilray is aggressively pivoting toward beverages and international medical/pharma expansion (notably BrewDog/Carlsberg and Australia/Germany deals) while its stock remains volatile amid investor skepticism over dilution and regulatory risk.
The beverage and international growth strategy could drive revenue upside long term but is likely to keep near‑term share volatility and investor caution high
Similar Companies in Healthcare
Other companies in the same sector with AI ratings